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Psoralen and UVA (PUVA) photochemotherapy is associ-
ated with a dose-dependent increased risk of nonmelan-
oma skin cancer in patients treated for psoriasis. Like
ultraviolet B radiation, PUVA is both mutagenic and
immunosuppressive and may thus act as a complete
carcinogen; however, the reversed squamous to basal cell
carcinoma ratio (SCC:BCC) in PUVA-treated patients,
also seen in immunosuppressed renal transplant recipi-
ents, suggests a possible cofactor role for human papil-
lomavirus (HPV) infection. In this study we examine a
large series of benign and malignant cutaneous lesions
for the presence of HPV DNA from patients treated with
high dose (ù500 J per cm2) ultraviolet A. A panel of
degenerate primers based on the L1 (major capsid protein)
open reading frame was employed, designed to detect
mucosal, cutaneous, and epidermodysplasia verruci-
formis HPV types with high sensitivity and specificity.
HPV DNA was detected in 15 of 20 (75%) non-melanoma
Psoralen and UVA (PUVA) photochemotherapy has beenwidely used in the treatment of inflammatory and malignantdermatoses for over 20 y. It is a highly effective and welltolerated treatment for many patients but its use is limitedby the associated risk of developing non-melanoma skin
cancer (NMSC) (Stern et al, 1979; Forman et al, 1989; Lindelo¨f et al,
1991; Bruynzeel et al, 1991; Chuang et al, 1992). The risk of squamous
cell carcinoma (SCC) in particular is increased up to 80-fold compared
with the normal population. Basal cell carcinomas (BCC) also occur
at a higher than expected frequency in PUVA patients (Stern and
Lange, 1988), although the increased risk is considerably less than for
SCC, resulting in a reversal of the usual BCC:SCC ratio similar to
that seen in immunosuppressed renal transplant recipients (RTR)
(Glover et al, 1993). It is reported that dysplastic keratoses occur in up
to 50% of patients treated with high dose PUVA (Lever and Farr,
1994), but typical virus warts are not commonly seen.
Several factors are thought to determine the risk of skin cancer in
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skin cancer, seven of 17 (41.2%) dysplastic PUVA kerat-
oses, four of five (80%) skin warts, and four of 12 (33%)
PUVA-exposed normal skin samples. The majority of
HPV positive lesions contained epidermodysplasia verru-
ciformis-related HPV including HPV-5, 220, 221, 223,
224, and 238. Possible novel epidermodysplasia verruci-
formis types were identified in further lesions. Mixed
infection with epidermodysplasia verruciformis, cutane-
ous, and/or mucosal types was present in six of 30 (20%)
of all HPV positive lesions, including in normal skin,
warts, dysplastic PUVA keratoses, and squamous cell
carcinomas. The prevalence and type of HPV infection
in cutaneous lesions from PUVA-treated patients is similar
to that previously reported in renal transplant-associated
skin lesions, and suggests that the role of HPV in PUVA-
associated carcinogenesis merits further study. Key words:
immunosuppression/photochemotherapy/viral carcinogenesis.
J Invest Dermatol 111:123–127, 1998
PUVA patients, including, in particular, cumulative UVA dose and
treatment number (reviewed in Studniberg and Weller, 1993). Sun
sensitive skin type and past exposure to ionizing radiation, arsenic, and
methotrexate may also be important factors. Psoralens intercalate
between complementary strands of DNA, particularly at A-T rich sites,
with formation of mono- and bi-functional adducts following photo-
activation by UVA radiation (Young, 1990). Mouse models provide
unequivocal evidence that PUVA is carcinogenic and recent studies
demonstrate a unique spectrum of p53 gene mutations in both mouse
and human PUVA-associated skin tumors (Nataraj et al, 1997); however,
PUVA has also been shown to induce cutaneous and systemic immuno-
suppression that may be an additional important determinant of its
carcinogenic potential (Strauss et al, 1980; Morison et al, 1983; Kripke
et al, 1983; Acalay et al, 1989; Ullrich, 1991). Precisely what part this
plays has yet to be established, but one possibility is that PUVA-
induced immunosuppression facilitates cutaneous HPV infection and
that this plays a role in the development of skin cancer in susceptible
individuals, as has been proposed in immunosuppressed RTR (Proby
et al, 1996).
In this study we report the detection of HPV DNA in a large series
of benign and malignant cutaneous lesions from 20 patients treated
with oral psoralen and ù500 J UVA per cm2.
MATERIALS AND METHODS
Patients Patients comprised 20 individuals (13 male, seven female; mean age
52.5 y, range 28–70 y) treated with ù500 J PUVA per cm2. Clinical details,
together with previous and current medication, are provided in Table I. Nine
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Table I. Clinical details of patientsa
Patient Sex Age (y) Disease Age (y) at Previous treatmentb Treatment at time Previous PUVA dose Skin typed
number onset of of biopsy NMSC (J per cm2)c
disease
1 M 35 AE ,5 UVB PUVA, topical steroids No 975 II
2 M 39 AE ,5 UVB topical steroids No 2367 II
3 M 70 CTCL 47 RT, EBT nil DK 600 II
(tumor stage)
4 M 64 CTCL 58 nil No 1723.5 II
(plaque stage)
5 M 42 CTCL 12 UVB, EBT PUVA SCC 1 BCC .5000 II
(plaque stage)
6 M 68 CTCL 56 UVB nil SCC .2000 III
(Sezary
syndrome)
7 F 58 Psoriasis 32 UVB, retinoids, MTX MTX DK 1640 II
8 M 70 Psoriasis 43 UVB nil DK 2814 II
9 M 49 Psoriasis 18 UVB topical steroids SCC 3810 II
10 M 53 Psoriasis 24 UVB topical steroids DK 724 II
11 M 59 Psoriasis 38 MTX UVB, topical steroids DK 945 III
12 M 70 Psoriasis 16 UVB UVB, topical steroids BCC 1103 III
13 F 50 Psoriasis 24 UVB, MTX, CYA topical steroids SCC 1 BCC 2407 III
14 M 42 Psoriasis 17 UVB UVB, topical steroids DK 2515 III
15 M 58 Psoriasis 26 UVB, retinoids, MTX Retinoids, topical steroids BCC 3274 III
16 F 37 Psoriasis 21 UVB topical steroids, CCT DK 5310 IV
17 F 59 Psoriasis 39 Retinoids, CYA, MTX Retinoids, CYA, MTX SCC 1 BCC 2448 III
18 F 47 Psoriasis UVB CYA, topical steroids SCC 2340 II
19 F 52 Psoriasis 22 UVB, retinoids topical steroids, CCT SCC 5000 III
20 F 28 PLE 14 nil No 500 II
aM, male; F, female; AE, atopic eczema; CTCL, cutaneous T cell lymphoma; PLE, polymorphic light eruption; UVB, ultraviolet B therapy; RT, radiotherapy; EBT, electron beam
therapy; MTX, methotrexate; CYA, cyclosporine A; CCT, crude coal tar; SCC, squamous cell carcinoma; BCC, basal cell carcinoma; PK, PUVA keratosis.
bIn all cases previous treatment included the use of topical steroids of varying potency. ‘‘Retinoids’’ refers to systemic retinoid therapy (etretinate or acitretin).
cCumulative PUVA dose at time of most recent biopsy.
dSkin type according to Fitzpatrick classification: I, always burn, never tan; II, always burn, usually tan; III, sometimes burn, always tan; IV, rarely burn, always tan.
had a history of NMSC, eight had developed dysplastic PUVA keratoses, and
four had had no premalignant or malignant skin lesions excised.
Tissue samples All lesions were histologically confirmed. Specimens included
20 NMSC (16 SCC, six BCC), four lesional psoriatic skin samples, 12 samples
of normal skin from 11 patients (one with atopic eczema, two with cutaneous
T cell lymphoma, one with polymorphic light eruption, and seven with
psoriasis) and samples of skin perilesional to two of the SCC. In addition, 22
keratotic skin lesions were excised, predominantly from the lower legs where
the majority of PUVA-associated skin malignancies occur. None of these
showed characteristic clinical features of a viral wart. None the less, on
histopathologic examination, five specimens were felt to be most consistent
with this diagnosis in that they showed hyperkeratosis, papillomatosis, and a
prominent granular layer with no evidence of dysplasia. Two were described
as squamous papillomas, two as squamous acanthomas, and one as a benign
keratoses. Seventeen other keratotic lesions were histologically characterized as
dysplastic PUVA keratoses; these showed varying degrees of hyperkeratosis and
acanthosis together with mild to moderate dysplasia but without evidence of
invasion. A focal lichenoid infiltrate was present in four of these specimens and
full-thickness bowenoid change in three others. Histopathologic features of
viral wart infection were not specifically noted in these lesions. Fifty-five
samples were snap-frozen and stored at –70°C. The remaining five SCC were
formalin-fixed and paraffin-embedded prior to DNA extraction.
DNA extraction DNA from frozen tissue was extracted by a standard
proteinase K/phenol-chloroform extraction technique (Sambrook et al, 1989).
DNA from paraffin-embedded tissue was similarly extracted after deparaffiniz-
ation. As a control for cross-contamination between samples, identical buffer
solutions that did not contain tissue were simultaneously subjected to an
identical purification process.
HPV detection All specimens were examined for the presence of HPV
DNA using a degenerate polymerase chain reaction (PCR)-based method. A
panel of oligonucleotide primers located within the highly conserved L1 (major
capsid protein) open reading frame of the HPV genome was designed to detect
all known cutaneous, epidermodysplasia verruciformis (EV), and mucosal HPV
types. Each specimen was tested with each of these primers.
PCR primers Mucosal HPV types were detected in a nested PCR using the
previously described primer pairs MY09/MY11 (Manos et al, 1989) as outer
primers and GP5/GP6 (Snijders et al, 1990) as nested primers (Table II).
Cutaneous HPV types were detected using the outer primer pair HVP2/B5
(Shamanin et al, 1994a, b) and three pairs of nested internal primers. The latter
were designed from published sequence data to detect the following HPV
groups (as defined in Chan et al, 1995); A2 (CN3F/CN3R), A4 (CN2F/
CN2R), and E (CN1F/CN1R). The cutaneous group B2 was detected using
a single round primer pair (C4F/C4R). EV-associated HPV types of group B1
were detected with the nested primer pairs CP62/69 and CP65/CP68 as
previously described.1 Three additional internal nested primer pairs were
designed internal to CP62/CP69 to detect the major EV-HPV clusters a1
(EN1F/EN1R), a2 (EN2F/EN2R), and b1/b2 (EN3F/EN3R).
By testing each set of primers against a panel of HPV plasmids, the reaction
conditions for all primers were optimized to allow detection of at least 10 fg
of episomal HPV DNA in a background of 100 ng of human placental DNA,
equivalent to 0.05 copies per cell. Prior to amplification with HPV primers, each
sample was amplified with b-globin primers to confirm adequate preservation of
DNA (Saiki et al, 1985).
PCR amplifications 100–200 ng of cellular DNA was used as a template in
each first round PCR reaction. PCR amplifications were performed exactly as
described for previously published primer pairs, with the additional use of GP5/
GP6 as an internal nested primer pair to MY09/MY11. For each nested PCR
amplification, 3 µl of the first round amplification product were used. For the
newly designed primers, amplification reactions were performed in 50 µl of
reaction mixture containing 1 U of AmpliTaq DNA polymerase (Perkin-Elmer,
New Jersey), GeneAmp 10X PCR Buffer II and 2 mM MgCl2 (supplied
by the manufacturer), 0.2 mM deoxynucleotide triphosphates (Advanced
Biotechnologies, Leatherhead, Surrey, U.K.), and 50 pmol of each primer.
Thirty cycles of PCR were performed (95°C for 1 min, 50°C for 1.5 min, and
72°C for 2 min) followed by extension at 72°C for 5 min. All PCR reactions
were performed on a Perkin-Elmer 480 thermal-cycler. For each set of reactions,
negative controls for reagents (water only) and DNA (human placental DNA)
1Berkhout RJM, Tieben LM, Bouwes Barinck JN, Vermeer BJ, ter Schegget
J: Novel nested PCR approach for detection of epidermodysplasia verruciformis-
associated HPV types in cutaneous cancers from nonimmunocompromised
patients. 14th International Papillomavirus Conference, Quebec City, 1995
(abstr.)
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Table II. Sequences of oligonucleotides used as primers
Primer set HPV group detecteda Sequence (59–39)b Size of product Annealing site
HVP2 General TCNMGNGGNCANCCNYTNGG HPV 18: 5934–5953
B5 AYNCCRTTRTTRTGNCCYTG 650 bp 6561–6580
C4F Group B1 GGAGATACAGAAAATCCT HPV 4: 5728–5746
C4R (HPV-4,48,50,60,65) SHATCTCCATAGATATCTTT 330–335 bp 6062–6082
CN1F Group E AATARGTTWGATGATGCWGAA HPV 1: 5793–5814
CN1R (HPV1,41,63) AKRTARTCWGGATATTTGCA 309–328 bp 6108–6128
CN3F Group A2 AACTCTAAYATWGCACATG HPV 3: 6140–6159
CN3R (HPV-3,10,28,29,77) CAVGTRCSYTGGCAAATATC 273 bp 6407–6427
CN2F Group A4 GGGGATATGGTTGAAACAGGT HPV 2: 6369–6360
CN2R (HPV-2,27,57) CAGAGGACACCATAGAGCCA 294 bp 6661–6681
CP62 EV types GTWAATGAAAYTTGYAANTATCC HPV 8: 6520–6543
CP69 (general) GWTAGATCWACATTCCARAA 690 bp 7231–7250
CP65 EV types CARGGTCAYAAYAATTGGYAT HPV 8: 6832–6851
CP68 (general) GGDACRAAACCYARYTGCCA 250 bp 7100–7120
EN1F EV cluster a1 TATTTCCCWACHGTHAGTGGCTC HPV 8: 6753–6776
EN1R (HPV-5,8,12,36,47) TCATAYTCYTCTACATGTCT 254 bp 6987–7007
EN2F EV cluster a2 CTGTCAGTGGCTCATTGGT HPV 14: 6524–6543
EN2R (HPV-14,19,20,21,25) CATWGCATTAATTTGAGCTA 314 bp 6818–6838
EN3F EV cluster b1 and b2 ATGKCWAATGATGTHTATGG HPV 23: 6367–6387
EN3R (HPV-9,15,17,37; 22,23,38) TGRTTRYYCCAYAAAATRCCATT 293 bp 6637–6660
MY11 Mucosal types GCMCAGGGWCATAAYAAYTGG HPV 6: 6722–6742
MY09 (general) CGTCCMARRGGAWACTGATC 450 bp 7150–7170
GP5 Mucosal types TTTGTTACTGTGGTAGATAC 150 bp
GP6 (general) GAAAAATAAACTGTAAATCA
aHPV groups as defined by Chan et al. (1995).
bDegenerate base code: N5G, A, C, or T; R5A or G; Y5T or C; W5A or T; M5A or C; D5G, A, or T; S5C or G; K5G or T; H5A, T, or C; V5G, A, or C.
were included and processed in the same way as the lesional samples throughout
all PCR steps, as were the negative controls for DNA extraction. None of the
negative controls was positive for HPV. HPV plasmid, 0.1 pg, containing the
genotype of HPV 1, 2, 3, 4, 5, or 6 served as positive controls in the appropriate
PCR reactions.
Sequence analysis Amplified PCR products that appeared as a visible band
after ethidium bromide staining were purified after separation in a 2% agarose
low melting point gel (Qiaquick Gel Extraction Kit, Qiagen, Germany) and
directly sequenced by fluorescent dideoxynucleotide chain termination cycle
sequencing (ABI Prism Dye Terminator Cycle Sequencing Ready Reaction
Kit, Perkin-Elmer) with both forward and reverse primers on a Perkin-Elmer
377 ABI Prism automated sequencer. The nucleotide sequences obtained were
analyzed using Sequence Navigator and Sequencing Analysis 2.1.1 computer
programs (Macintosh) and compared with those of known HPV types available
through the GenBank database (National Center for Biotechnology Information,
National Institutes of Health, Bethesda, MD). A nucleotide sequence was
regarded as an HPV type if it shared over 90% homology with a known type
and a related type if the sequence homology was less than this (de Villiers, 1994)
RESULTS
HPV DNA was found in 15 of 20 (75%) NMSC (11 of 14 SCC and
four of six BCC) from eight individuals, seven of whom had at least
one HPV positive lesion (Table III). Seven of 17 (41.2%) dysplastic
PUVA keratoses from five individuals were positive, as were four of
five (80%) warts from four patients. HPV was identified in four of 12
(33%) of PUVA-exposed normal skin samples from 11 patients;
however, HPV DNA was not found in four samples of psoriasis from
a single patient who none the less harboured HPV in a dysplastic
PUVA keratosis.
EV-associated HPV types predominated in all lesions with HPV-5,
-5-related, -20, -38, -RTRX9, and -ICPX1 being found in 12 of 15
positive NMSC from six patients and HPV-5 and -24 in three of seven
positive dysplastic PUVA keratoses in four patients. HPV-3, -5, and
two potentially novel EV-related types (HPV-36-related and HPV-15-
related) were identified in virus warts and types -21, -23, and
-RTRX2 were found in three normal skin samples. Six lesions from
four individuals contained mixed infections with EV, cutaneous, and/
or mucosal types. Cutaneous HPV types alone were found in three
dysplastic keratoses and in two SCC from two patients. Lesions
containing mucosal HPV only were obtained from three patients; type
11 was found in one dysplastic keratosis and HPV-MM8 and HPV-16
in two further SCC.
DISCUSSION
This study is the first to employ a panel of degenerate primers in
examining a large series of PUVA-associated skin lesions. These primers
were designed to detect the widest possible range of HPV types with
high specificity and sensitivity. The results justify the use of this
comprehensive panel, demonstrating a high prevalence and a wide
range of HPV types in diverse cutaneous lesions, including PUVA-
exposed normal skin, which would not have been detectable if single
primer sets had been employed (Surentheran T, Harwood CA, and
Spink PJ, in press). EV types predominated in all lesions and mixed
infection was frequently seen with cutaneous, mucosal, and EV HPV
types together in individual lesions of normal skin, wart, and SCC.
HPV-5 was frequently detected in both benign and malignant PUVA
lesions, being present in 10 of 30 (33%) of HPV positive skin biopsies
from four individuals.
To our knowledge there have been just four previous reports of
HPV in PUVA-associated skin lesions. These were small studies or
case reports using more limited methods than those reported here. In
separate reports, HPV-16/18 was found in SCC from two individuals
with multiple skin cancers following high dose PUVA treatment for
psoriasis (Weinstock et al, 1995; Rubben et al, 1996). In a third case,
a single benign lesion from a patient with a history of PUVA-associated
skin cancers was shown to contain HPV-5 (Bayle-Lebey et al, 1994).
Finally, HPV-41 was identified in four SCC in one series, three of
which were PUVA-associated lesions (Hirt et al, 1990); however, in
each of these studies the detection technique used meant that the
presence of other HPV types and mixed infection could not be excluded.
The previous reports of HPV-16/18 in multiple tumors from two
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Table III. HPV typing of individual lesionsa
HPV types detectedb
Patient number Normal skin Psoriasis Warts DK SCC BCC






5 23 5 (i) 5 (i) 5 (i) 5
(ii) neg (ii) 5 (ii) 5

















15 neg (i) 11 neg
(ii) neg
(iii) neg
16 (i) neg (i) 27
(ii) neg (ii) neg
(iii) neg
(iv) neg




18 6 (i) 38 [peri 5 9]
(ii) 38 [peri 5 38]
19 neg neg ICPx1d
20 neg
aDK, dysplastic PUVA keratosis; BCC, basal cell carcinomas; SCC, squamous cell carcinoma.
bHPV types detected in individual lesions. Where more than one lesion of a given type has been analyzed for an individual, the lesions are listed by Roman numeral. neg, a PCR
negative sample; rel, a related HPV type; peri, histologically normal tissue perilesional to the lesion indicated; the three samples recorded were not included in the calculations relating to
the HPV typing of normal tissue samples.
cCodetection of two or more HPV types in a single lesion.
dHPV sequences available in the GenBank database for which the full genome sequence has not yet been published – locus names and accession numbers are given in parentheses:
RTRx2 (HPVRTRX2, L38919), RTRx9 (HPVRTRX9, U85662), MM8 (HPVMM8, U12490), ICPx1 (HPVICPX1, L38914).
patients is particularly notable because the so-called ‘‘high risk’’ types
are closely associated with anogenital cancers and are rarely reported
in cutaneous SCC, even in immunosuppressed patients. Cutaneous
periungual SCC may be an exception to this (Moy et al, 1989; Eliezri
et al, 1990; McGregor and Proby, 1996); however, our results suggest
that HPV-16/18 infection is not representative of the majority of
PUVA-associated skin tumors; only two samples in our series contained
HPV-16, one of them an SCC and the other a normal skin sample in
which HPV-1 and RTRX2 were also detected. We did identify other
mucosal HPV types in five further lesions comprising two SCC, two
keratoses, and one sample of normal skin, but we found that it was
EV rather than mucosal HPV types that predominated, a spectrum
closer to that recently reported in skin cancers in both RTR and
immunocompetent patients (Berkhout et al, 1995; de Jong-Tieben
et al, 1995; Shamanin et al, 1996).
With the recent development of degenerate and nested primers
sensitive and specific enough to detect most known cutaneous and
EV-associated HPV types, consistent results are now reported by
independent investigators that demonstrate a strong association between
HPV DNA and NMSC, predominantly in RTR but also, at lower
frequency and in smaller series of tumors, in otherwise healthy
individuals with skin cancer (Berkhout et al, 1995; Shamanin et al,
1996). Discrepancies in the prevalence and in the type of HPV DNA
reported by separate investigators in skin cancers of similar etiology
most likely reflects the different methodologies used, rather than
differences between groups of patients (Proby et al, 1996). Generally,
EV-associated HPV types predominate, as in our series of PUVA-
associated skin lesions, the prevalence of HPV detection being higher
in immunosuppressed than in nonimmunosuppressed patients, but with
no particular HPV type being consistently found. Mixed infection
with several different HPV types is frequently reported in transplant-
associated skin lesions, but not in immunocompetent patients, and was
also found in our series of PUVA-associated cutaneous lesions, perhaps
reflecting the extent to which PUVA causes cutaneous immunosuppres-
sion. In addition, however, many patients with extensive, resistant
psoriasis requiring high dose PUVA, such as those represented in this
study, are often also treated with other immunosuppressive therapies.
We found a higher prevalence of HPV-5 in our series of PUVA
skin lesions than that previously reported to be detected in renal
transplant patients, but it is not clear whether this will prove significant.
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HPV-5 is frequently found in benign and malignant skin lesions in EV
patients who are genetically susceptible to HPV infection (Majewski
and Jablonska, 1995), and was also reported in early studies of RTR
skin cancers that used less specific DNA hybridization techniques for
HPV identification (Lutzner et al, 1983; Barr et al, 1989). In more
recent PCR-based studies it is rarely identified, even when type-
specific primers have been used (Stark et al, 1994).
In summary, this study extends the spectrum of skin cancers of
differing etiology in which a high prevalence and a broad range of
HPV DNA is detectable; however, despite the strong association
between HPV and NMSC that is emerging, HPV DNA is also detected
in normal skin samples (Stark et al, 1994) and in hair follicles from
immunosuppressed patients (Boxman et al, 1997). We similarly found
HPV DNA in samples of PUVA-exposed normal skin and hence the
relevance of these findings to carcinogenesis remains to be established.
One possibility is that PUVA facilitates cutaneous HPV infection or,
alternatively, activates latent HPV infection, and that this is relevant to
the subsequent development of skin cancer in susceptible individuals.
It is also possible that HPV DNA is found in NMSC as a ‘‘passenger,’’
PUVA and sunlight playing a causal role in increasing susceptibility to
both cutaneous viral infection and skin cancer independently. Studies
designed to address these possibilities are currently underway.
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